Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Georgina V. Long(The University of Sydney), Reinhard Dummer(University Hospital of Zurich), Jacob Schachter, Barbara Merelli(Ospedale Papa Giovanni XXIII), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Marta Nyakas(Oslo University Hospital), Thierry Lesimple, Dirk Schadendorf(National Center for Tumor Diseases), Monique Tan(Heidelberg University), Axel Hauschild(University Hospital Schleswig-Holstein), Ruth Plummer(National Health Service), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), James Larkin(Trinity College Dublin), Laurent Mortier, Mario Santinami(Fondazione IRCCS Istituto Nazionale dei Tumori), Andrew Haydon(The Alfred Hospital), Sachin Bajirao Adnaik(Princess Alexandra Hospital), Tarveen Jandoo(Princess Alexandra Hospital), Caroline Robert(Institut Gustave Roussy), Paul Burgess(Princess Alexandra Hospital), John M. Kirkwood(UPMC Hillman Cancer Center), Victoria Atkinson(Greenslopes Private Hospital), Mario Mandalà(University of Perugia)
Cited by 123
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k